Agenus (AGEN) Posts Quarterly Earnings Results, Misses Expectations By $0.12 EPS

Agenus (NASDAQ:AGEN) issued its earnings results on Thursday. The biotechnology company reported ($0.40) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.12), MarketWatch Earnings reports.

NASDAQ:AGEN traded down $0.01 during trading hours on Thursday, hitting $2.95. 1,071,161 shares of the stock traded hands, compared to its average volume of 1,550,627. Agenus has a fifty-two week low of $1.54 and a fifty-two week high of $6.02. The company has a market cap of $336.00 million, a P/E ratio of -2.40 and a beta of 2.09.

A number of brokerages have commented on AGEN. Zacks Investment Research upgraded Agenus from a “sell” rating to a “hold” rating in a research note on Thursday, January 24th. ValuEngine downgraded Agenus from a “buy” rating to a “hold” rating in a research note on Thursday, January 31st. Finally, BidaskClub downgraded Agenus from a “buy” rating to a “hold” rating in a research note on Friday, January 25th.

Several hedge funds and other institutional investors have recently bought and sold shares of AGEN. Amalgamated Bank bought a new stake in Agenus in the fourth quarter worth $30,000. Two Sigma Securities LLC acquired a new stake in shares of Agenus during the fourth quarter worth approximately $31,000. Legal & General Group Plc increased its holdings in shares of Agenus by 47.7% during the fourth quarter. Legal & General Group Plc now owns 21,674 shares of the biotechnology company’s stock worth $52,000 after buying an additional 7,002 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Agenus by 272.8% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,105 shares of the biotechnology company’s stock worth $76,000 after buying an additional 23,493 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY bought a new stake in shares of Agenus during the fourth quarter valued at approximately $80,000. 31.77% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Agenus (AGEN) Posts Quarterly Earnings Results, Misses Expectations By $0.12 EPS” was reported by WKRB News and is the property of of WKRB News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.wkrb13.com/2019/03/14/agenus-agen-posts-quarterly-earnings-results-misses-expectations-by-0-12-eps.html.

Agenus Company Profile

Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.

Read More: What is a Fiduciary?

Earnings History for Agenus (NASDAQ:AGEN)

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.